Ecalta (anidulafungin)
- Region
- 🇪🇺 EU
- Active substance
- anidulafungin
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Candidiasis
- EU approval
- Thu 20 Sep 2007
- Application
- EMEA/H/C/000788
- ATC
- J02AX06
- Official record
- www.ema.europa.eu
Indication
Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.
Regulatory milestones
No milestones recorded in the last year.
Follow Ecalta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.